# Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)

> **NCT05685940** · PHASE4 · UNKNOWN · sponsor: **University Hospital, Ghent** · enrollment: 100 (estimated)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **PROCEDURE:** Venapuncture
- **PROCEDURE:** Patient questionnaires

## Key facts

- **NCT ID:** NCT05685940
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-05
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05685940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05685940, "Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05685940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*